Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 5INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Tumor-Agnostic 2Thoracic 2Myeloid 2Lymphoid 1Gynecologic 1

Conditions

Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Myelodysplastic Syndromes 2Hematologic Diseases 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Acute Disease 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × vosaroxin × Other hematologic neoplasm × Clear all
NCT01191801 2018-08-22

VALOR

Sunesis Pharmaceuticals

Phase 3 Completed
711 enrolled 15 charts
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT00541866 2018-01-09

Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans

Sunesis Pharmaceuticals

Phase 1/2 Completed
110 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT00607997 2017-06-28

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Sunesis Pharmaceuticals

Phase 2 Completed
113 enrolled 25 charts
MyeloidOther hematologic neoplasm

Acute Disease, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Sunesis Pharmaceuticals

Phase 1 Completed
75 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡